A clinical trial to study the effects of two drugs, R-TPR-023 and Avastinâ?¢ in patients with Metastatic colorectal cancer

Intervention1: R-TPR-023: Dose: 5 mg/kg, Frequency: Every 2 weeks, Route of Administration: Intravenously, Duration: 3 years. Control Intervention1: Avastinâ?¢: Dose: 5 mg/kg, Frequency: Every 2 weeks, Route of Administration: Intravenously, Duration: 3 years Primary outcome(s): Outcome Name: Efficacy will be assessed as Objective Response Rate (Complete Response and Partial Response) by RECIST 1.1 criteria at 25 weeksTimepoint: 25 weeks Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label